F Ballanger1, J M Nguyen, A Khammari, B Dréno. 1. Department of Cancer Dermatology, INSERM U892, University Hospital Hôtel-Dieu, Place Alexis Ricordeau, Nantes, France.
Abstract
BACKGROUND: The mechanisms of action of bexarotene are not well understood. METHODS: A retrospective study on patients with cutaneous T-cell lymphoma (CTCL) treated with bexarotene was performed to see if bexarotene could act on the dominant T-cell clones. Thirty-five patients were included. Twenty-three were treated with bexarotene for more than 3 months (300 mg/m(2)). In 7 patients, phototherapy was given with bexarotene. RESULTS: Dominant T-cell clones were observed in 11 patients in peripheral blood and in 19 patients in skin. Our results demonstrate no significant evolution of T-cell clones either in skin or peripheral blood. Furthermore, the detection of T-cell clones in peripheral blood before starting bexarotene was significantly associated with the progression of the disease. UV therapy given with bexarotene significantly improved therapeutic response without any correlation with T-cell clones. CONCLUSION: This is the first study on the evolution of the T-cell clone in blood and skin in CTCL patients during bexarotene therapy. Copyright (c) 2010 S. Karger AG, Basel.
BACKGROUND: The mechanisms of action of bexarotene are not well understood. METHODS: A retrospective study on patients with cutaneous T-cell lymphoma (CTCL) treated with bexarotene was performed to see if bexarotene could act on the dominant T-cell clones. Thirty-five patients were included. Twenty-three were treated with bexarotene for more than 3 months (300 mg/m(2)). In 7 patients, phototherapy was given with bexarotene. RESULTS: Dominant T-cell clones were observed in 11 patients in peripheral blood and in 19 patients in skin. Our results demonstrate no significant evolution of T-cell clones either in skin or peripheral blood. Furthermore, the detection of T-cell clones in peripheral blood before starting bexarotene was significantly associated with the progression of the disease. UV therapy given with bexarotene significantly improved therapeutic response without any correlation with T-cell clones. CONCLUSION: This is the first study on the evolution of the T-cell clone in blood and skin in CTCLpatients during bexarotene therapy. Copyright (c) 2010 S. Karger AG, Basel.
Authors: Kelly A Chamberlain; Sonia E Nanescu; Konstantina Psachoulia; Jeffrey K Huang Journal: Neuropharmacology Date: 2015-10-22 Impact factor: 5.250
Authors: Jeffrey K Huang; Stephen P J Fancy; Chao Zhao; David H Rowitch; Charles Ffrench-Constant; Robin J M Franklin Journal: Neurotherapeutics Date: 2011-10 Impact factor: 7.620